ArticlePediatric surgery international2026
Oral gastrografin protocol resolves worm-induced small bowel obstruction in children: a prospective cohort study.
Article in Pediatric surgery international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundWorm-induced small bowel obstruction (SBO) is a common pediatric surgical problem in endemic regions, but the role of oral Gastrografin in this setting remains unclear.
methodsWe conducted a prospective cohort study (December 2022–December 2024) at a single center in Pakistan. Children aged 5–18 years with radiological and clinical evidence of uncomplicated Ascaris-related SBO were included. Exclusions were complicated obstruction, rectal bleeding, hypersensitivity to Gastrografin, or refusal to participate. Participants received either standard conservative management (nil per os, nasogastric decompression, intravenous fluids, antibiotics, enemas, antispasmodics) or the same regimen plus Gastrografin 2 mL/kg via nasogastric tube (diluted 1:1 with saline). The primary outcome was hospital length of stay (LOS). Secondary outcomes were time to oral intake, pain resolution, passage of flatus and stool, laparotomy, and in-hospital complications.
resultsOne hundred and twenty children were enrolled (60 per group). Baseline characteristics were similar. Gastrografin was associated with a shorter LOS (35 ± 15 vs. 60 ± 15 h; mean difference − 25.0, 95% CI − 30.4 to − 19.6; p < 0.001). Recovery milestones occurred earlier, including oral intake (30.2 ± 6.0 vs. 60.5 ± 15.6 h), pain resolution (14.2 ± 4.5 vs. 45.8 ± 12.4 h), passage of flatus (20.9 ± 9.0 vs. 48.8 ± 12.1 h), and stool (15.9 ± 8.0 vs. 48.8 ± 12.1 h) (all p ≤ 0.002). Laparotomy was infrequent (3/60 vs. 5/60; p > 0.05). No Gastrografin-related adverse events occurred under hydration protocols.
conclusionsIn this cohort, oral Gastrografin as an adjunct to conservative care was associated with faster recovery and shorter hospitalisation without new safety concerns. Multicenter randomized studies are needed to confirm effectiveness and guide standardised protocols.
Indexed as
Identifiers
41838172What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.